348 related articles for article (PubMed ID: 36794675)
41. Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).
Kumru OS; Bajoria S; Kaur K; Hickey JM; Van Slyke G; Doering J; Berman K; Richardson C; Lien H; Kleanthous H; Mantis NJ; Joshi SB; Volkin DB
Hum Vaccin Immunother; 2023 Aug; 19(2):2264594. PubMed ID: 37932241
[TBL] [Abstract][Full Text] [Related]
42. RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
Phatarphekar A; Vidyadhar Reddy GEC; Gokhale A; Karanam G; Kuchroo P; Shinde K; Masand G; Pagare S; Khadpe N; Pai SS; Vijayan V; Ramnath RL; Pratap Reddy K; Rao P; Harinarayana Rao S; Ramana V
Vaccine; 2022 Jul; 40(32):4522-4530. PubMed ID: 35718590
[TBL] [Abstract][Full Text] [Related]
43. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
44. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
Phoolcharoen W; Shanmugaraj B; Khorattanakulchai N; Sunyakumthorn P; Pichyangkul S; Taepavarapruk P; Praserthsee W; Malaivijitnond S; Manopwisedjaroen S; Thitithanyanont A; Srisutthisamphan K; Jongkaewwattana A; Tomai M; Fox CB; Taychakhoonavudh S
Vaccine; 2023 Apr; 41(17):2781-2792. PubMed ID: 36963999
[TBL] [Abstract][Full Text] [Related]
45. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
46. α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants.
Zou J; Jing H; Zhang X; Liu Y; Zhao Z; Duan L; Yuan Y; Chen Z; Gou Q; Xiong Q; Li S; Yang F; Zeng H; Zou Q; Zhang J
Front Immunol; 2021; 12():757691. PubMed ID: 34630436
[TBL] [Abstract][Full Text] [Related]
47. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.
Liu Z; Zhou J; Xu W; Deng W; Wang Y; Wang M; Wang Q; Hsieh M; Dong J; Wang X; Huang W; Xing L; He M; Tao C; Xie Y; Zhang Y; Wang Y; Zhao J; Yuan Z; Qin C; Jiang S; Lu L
Cell Res; 2022 Mar; 32(3):269-287. PubMed ID: 35046518
[TBL] [Abstract][Full Text] [Related]
48. Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2.
Lobaina Y; Chen R; Suzarte E; Ai P; Huerta V; Tan C; Alvarez-Lajonchere L; Liling Y; Musacchio A; Silva R; Guillén G; Zaixue J; Yang K; Perera Y; Hermida L
Arch Virol; 2023 Jun; 168(7):190. PubMed ID: 37351679
[TBL] [Abstract][Full Text] [Related]
49. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
50. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
51. A Trim-RBD-GEM vaccine candidate protects mice from SARS-CoV-2.
Su R; Shi Z; Li E; Zhu M; Li D; Liu X; Sun Y; Feng N; Wang J; Wang T; Xia X; Sun W; Gao Y
Virology; 2023 Aug; 585():145-154. PubMed ID: 37348143
[TBL] [Abstract][Full Text] [Related]
52. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
53. Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model.
Shrivastava T; Singh B; Rizvi ZA; Verma R; Goswami S; Vishwakarma P; Jakhar K; Sonar S; Mani S; Bhattacharyya S; Awasthi A; Surjit M
Front Immunol; 2021; 12():641447. PubMed ID: 34108961
[TBL] [Abstract][Full Text] [Related]
54. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
Barbey C; Su J; Billmeier M; Stefan N; Bester R; Carnell G; Temperton N; Heeney J; Protzer U; Breunig M; Wagner R; Peterhoff D
Eur J Pharm Biopharm; 2023 Nov; 192():41-55. PubMed ID: 37774890
[TBL] [Abstract][Full Text] [Related]
55. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
Wørzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Karlsson Hedestam GB; Murrell B; Christensen D; Pedersen GK
EBioMedicine; 2021 Jan; 63():103197. PubMed ID: 33422991
[TBL] [Abstract][Full Text] [Related]
56. Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice.
Ke Q; Sun P; Wang T; Mi T; Xu H; Wu J; Liu B
J Immunol Methods; 2022 Jul; 506():113279. PubMed ID: 35533747
[TBL] [Abstract][Full Text] [Related]
57. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
58. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
59. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
60. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
